During the coronavirus disease 2019 (COVID-19) pandemic, burnout has become prevalent among gastroenterologists in Southeast Asia, driven strongly by fears of getting infected and the stress of reduced income, according to a Singapore study presented at the recently concluded Asian Pacific Digestive Week 2021 (APDW 2021).
The first large-scale population-based study on the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and Bell’s palsy finds a small increase in risk of developing the condition among recipients of the CZ02 (CoronaVac) inactivated vaccine.
The presence of gastrointestinal (GI) symptoms does not appear to significantly contribute to any clinical outcomes in adult patients admitted for COVID-19, reveals a retrospective study in the Philippines.
Although both the BNT162b2 and ChAdOx1 nCoV-19 vaccines appear to be effective against symptomatic disease caused by the delta variant of the SARS-CoV-2 virus, the effectiveness is lower than that against the alpha variant. However, this reduced effectiveness was less pronounced after two doses of the vaccine, a recent study from England showed.
Concomitant or sequential administration of the combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine and the tetravalent dengue vaccine (CYD-TDV; sold under the brand name Dengvaxia) produces similar immunogenicity and safety profiles in baseline dengue seropositive participants, a Philippines study has shown.
The use of the anti-inflammatory drug colchicine in an outpatient setting may reduce the risk of COVID-19–related death or hospitalization in patients with PCR-confirmed COVID-19, according to results of the phase III COLCORONA* trial.